GlassScriptPhysician profile
Lawrence P Landwehr
NPI 1265599591
$6,428.97
in general payments reported to CMS, 2019-2025
31 companies · $629 in 2025
The $629 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,230 · 2020: $662 · 2021: $829 · 2022: $677 · 2023: $717 · 2024: $684 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $1,696.03 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $1,556.63 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Csl Behring | $529.58 | 2019-2025 | Haegarda, Hizentra, Andembry |
| Kaleo, INC. | $474.09 | 2019-2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $340.73 | 2019-2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $317.37 | 2021-2025 | Dupixent |
| Genzyme Corporation | $261.61 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $180.14 | 2019-2025 | |
| Sunovion Pharmaceuticals INC. | $139.01 | 2019 | |
| Amgen INC. | $120.27 | 2022-2025 | Tezspire |
| Optinose US, INC. | $106.11 | 2020-2024 | |
| Grifols USA, LLC | $94.27 | 2019-2024 | Xembify |
| Takeda Pharmaceuticals U.S.A., INC. | $82.49 | 2020-2025 | Takhzyro, Cuvitru |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.73 | 2019-2021 | |
| Biocryst US Sales Co., LLC | $63.91 | 2021-2023 | Orladeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bio Products Laboratory USA, INC. | $61.37 | 2021-2022 | |
| Lilly USA, LLC | $59.60 | 2025 | Ebglyss |
| Teva Pharmaceuticals USA, INC. | $33.59 | 2020 | |
| Shire North American Group INC | $33.57 | 2019 | |
| Genentech USA, INC. | $28.41 | 2019-2020 | |
| Leo Pharma INC. | $27.27 | 2023 | Adbry |
| Pharming Healthcare, INC. | $23.67 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $23.66 | 2025 | Neffy |
| Hikma Pharmaceuticals USA | $23.63 | 2024 | Ryaltris |
| Galderma Laboratories, L.P. | $18.03 | 2025 | Nemluvio |
| Abbvie INC. | $17.08 | 2025 | |
| Circassia INC. | $14.35 | 2019 | |
| Hospira, INC. | $13.66 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.11 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Landwehr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.